CVCees B. de Vos

Cees B. de Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cees B. de Vos has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving the accUracy of Referrals to the emerGency departmEnt of patieNts with chesT pain using the modified HEART score in Emergency Medical Transport (URGENT 2.0): protocol for a multicentre randomised controlled trial

    by Lisa D S Frenk, Braim M Rahel, Cees B de Vos, Frits H M van Osch, Fabiana G Prestigiacomo, Marcel J W Janssen, Robert T A Willemsen, Arnoud W van 'T Hof, Joan G Meeder

    Introduction Ischaemic heart disease is the single most common cause of death worldwide. Traditionally, distinguishing patients with cardiac ischaemia from patients with less alarming disease, in prehospital triage of chest pain, is challenging for both general practitioners and ambulance paramedics. Less than 20% of patients with chest pain, transferred to the emergency department (ED), have an acute coronary syndrome (ACS) and the transportation and analysis at the ED of non-ACS patients result in substantial healthcare costs and a great patient burden. Advanced risk stratification, with the help of cardiac troponin measurements, seems crucial to improve prehospital diagnostic accuracy. Methods and analysis The URGENT 2.0 trial is a randomised controlled trial in which the primary objective is to reduce the referral of non-cardiac chest pain (NCCP) patients, using a modified HEART score including a high-sensitivity capillary point-of-care high-sensitivity cardiac troponin I measurement. Patients are included by ambulance paramedics and 1:1 randomised for (1) regular care (control group) or (2) modified HEART score analysis (intervention group) and non-referral in case of a low modified HEART score (0–3). In total, 852 patients will be included. Follow-up will be performed at 30 days, 6 months and 12 months. Both referral rates of NCCP patients and the occurrence of major adverse cardiac events are defined as primary outcome measures. Ethics and dissemination The medical ethics committee Zuyderland-Zuyd Hogeschool (Netherlands) has approved this trial (reference numbers NL71820.096.19 and METCZ20190139). Written informed consent will be obtained from all participating patients. The results of this trial will be disseminated in one main paper and in additional papers with subgroup analyses. Trial registration ClinicalTrials.gov, NCT04904107.


  • Antiaritmica

    by C.B. de Vos, H.J.G.M. Crijns

  • Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation

    by Stefano Fumagalli, Robby Nieuwlaat, Francesca Tarantini, Cees B. de Vos, Christ J. Werter, Jean-Yves Le Heuzey, Niccolò Marchionni, Harry J. G. M. Crijns


  • Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation.

    by Stefano Fumagalli, Robby Nieuwlaat, Francesca Tarantini, Cees B De Vos, Christ J Werter, Jean-Yves Le Heuzey, Niccolò Marchionni, Harry J G M Crijns

    Atrial fibrillation (AF) is the most frequent sustained arrhythmia of elderly patients, in whom it determines an increase in morbidity and mortality. Aim of this study was to assess age-related differences in the characteristics, management and prognosis of patients with AF in European cardiology practices. The Euro Heart Survey on AF was an observational study sponsored by the European Society of Cardiology. Patients were enrolled between 2003 and 2004 in 182 hospitals of 35 countries. For the purposes of this study, they were categorized into three age-groups: 80 years (n=671). Follow-up was closed in 2005. Compared with general population estimates, patients >80 years were underrepresented in the Euro Heart Survey. The oldest patients were less likely to be enrolled by university or specialized centers, to receive extensive diagnostic testing, and to receive oral anticoagulation despite a worse stroke risk profile. Furthermore, the oldest patients less often received rhythm control therapy, even when presenting with palpitations and non-permanent AF. During 1 year follow-up, elderly patients more often suffered a myocardial infarction, new onset heart failure and major bleedings. They had higher all-cause and cardiovascular mortality. Elderly patients with AF are less often referred to the cardiologist and, based on current guidelines, are inadequately studied and treated, compared to younger counterparts. Education on evidence- based management and the design of randomized controlled trials specifically targeting the elderly, should improve the management and prognosis of this frail segment of the AF population.


  • Atrial Fibrillatory Wall Motion and Degree of Atrial Remodeling in Patients with Atrial Fibrillation: A Tissue Velocity Imaging Study

    by Cees B. DE Vos, Laurent Pison, Ron Pisters, Ulrich Schotten, Emile C. Cheriex, Martin H. Prins, Tammo Delhaas, Harry J.G.M. Crijns, Robert G. Tieleman

    Introduction: The atrial fibrillation cycle length (AFCL) and the intracardiac atrial electrogram morphology may be used to characterize atrial fibrillation (AF). However, assessment of these parameters requires an invasive electrophysiological study. We assessed clinical and electrophysiological correlates of noninvasive tissue velocity imaging (TVI) of the right and left atrial myocardial fibrillatory wall motion. Methods and Results: We performed an electrophysiological study in 12 patients with AF referred for His bundle ablation. Using atrial electrograms, we determined the AFCL (AFCL‐egm) and electrophysiological AF type. Simultaneously, transthoracic echocardiography was performed. We used the TVI traces to determine the cycle length of the atrial fibrillatory wall motion (AFCL‐tvi) and atrial fibrillatory wall velocities (AFV‐tvi). AFCL‐tvi matched very well with AFCL‐egm (r2= 0.98; P < 0.001), both in the left and right atrium. Patients with permanent AF had shorter AFCL‐tvi (155 ± 15 ms vs 216 ± 23 ms; P < 0.001), higher AFCL‐tvi variability, and lower AFV‐tvi compared to patients with paroxysmal AF. Three electrophysiological AF types were found based on the morphology of the electrograms and these related to specific TVI patterns. Conclusion: TVI of the atrial fibrillatory wall motion may enhance noninvasive characterization of atrial remodeling in patients with atrial fibrillation.


  • Open Access

    Undetected paroxysmal atrial fibrillation in chronic heart failure patients: is it clinically relevant to catch the atrial phantom?

    by Ron Pisters, Cees B. de Vos, Robert Dennert, Harry J. Crijns

    Chronic heart failure (CHF) is frequently accompanied by atrial fibrillation (AF). How often AF occurs in CHF patients is difficult to know since many episodes come and go undetected because of lacking symptoms. Therefore, assessing the total burden of AF calls for continuous rhythm monitoring. At present, we do not know whether assessing burden of AF is clinically relevant. Furthermore, we do not know whether AF has any impact on survival in CHF patients, since previous clinical studies show conflicting results.